Your browser doesn't support javascript.
Using the galectin-3 test to predict mortality in heart failure patients: a systematic review and meta-analysis.
Biomark Med ; 10(3): 329-42, 2016.
Artigo em Inglês | MEDLINE | ID: mdl-26860036
ABSTRACT

AIM:

Galectin-3 (Gal-3) is a new biomarker for assessing prognosis of heart failure (HF) patients. This systemic review and meta-analysis aims to examine Gal-3's ability in assessing prognosis of HF patients.

METHOD:

We searched MEDLINE and Embase up to November 2014. Test performance characteristics were summarized using forest plots and hierarchical summary receiver operating characteristic curves.

RESULTS:

The diagnostic odds ratio of Gal-3 in predicting mortality in chronic HF patients was 2.36 (95% CI 1.71-3.26) and 2.30 (95% CI 1.76-3.01) in acute HF patients.

CONCLUSION:

Elevated levels of Gal-3 are associated with mortality in both acute and chronic HF patients. However, current evidence does not support sole use of Gal-3 for prognosis evaluation of HF patients.
Assuntos

Similares

MEDLINE

...
LILACS

LIS

Texto completo: Disponível Coleções: Bases de dados internacionais Base de dados: MEDLINE Assunto principal: Galectina 3 / Insuficiência Cardíaca Tipo de estudo: Revisão sistemática Aspecto clínico: Predição / Prognóstico Limite: Humanos Idioma: Inglês Revista: Biomark Med Assunto da revista: Bioquímica / Medicina Ano de publicação: 2016 Tipo de documento: Artigo País de afiliação: Taiwan